CO.DON
CO.DON develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient’s own cartilage cells. More than 20,000 patients have already been treated with CO.DON’s method. In January 2023, CO.DON GmbH was acquired by ReLive Biotechnologies, a global company headquartered in the US. CO.DON currently has two locations in Germany as well as subsidiaries or sales partnerships in the Netherlands, the United Kingdom and Austria.
Work in m2M
CO.DON will establish a high-level early-stage roadmap required for regulatory approval to support the work done by its m2M partners BioM and UMCU-ICAT. This will strategically guide the m2M consortium leader and will be used to ensure alignment within groups to set baseline requirements to bring the foreseen bioprinted products to market.
Furthermore, in the final year of the m2M project, a strategic translational feasibility assessment and regulatory planning will be executed, to focus on improving investor readiness by detailing the medical needs e.g., thus optimizing the development plan according to commercial realities. A regulatory strategy tailored to the product’s intended market and regulatory requirements will be developed.
Researchers involved
